Gene Therapy by Administration of Genetically Engineered CD34+ Obtained by Cord Blood
Description of Invention:
This invention provides a method of providing a therapeutic effect in human patients by administering to the patient CD34+ cells obtained from umbilical cord blood. The CD34+ cells have been engineered with at least one nucleic acid sequence encoding a therapeutic agent. Such CD34+ cells could be engineered by transducing the cells with a retroviral vector including the nucleic acid sequence encoding the therapeutic agent. This method has been applied in treating new born infants suffering from adenosine deaminase (ADA) deficiency. This application was filed pre-GATT and is therefore valid 17 years from issued date of January 10, 2006.
Inventors:
Robert M. Blaese (NCI) et al.
Patent Status:
DHHS Reference No. E-045-1995/0 --
U.S. Patent No. 6,984,379 issued 10 Jan 2006
Licensing Status: In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
Portfolios: Gene Based Therapies
Gene Based Therapies -Therapeutics-Gene Therapy-Therapeutic Genes Gene Based Therapies -Therapeutics-Gene Therapy-Delivery Systems Gene Based Therapies -Therapeutics
For Additional Information Please Contact: John Stansberry Ph.D.
NIH Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-5236
Email: stansbej@mail.nih.gov
Fax: (301) 402-0220
